miR-29a-3p is involved in gastric and breast cancer, as well as colorectal cancer and hepatocarcinoma (Li Y. et al., 2020; Wang J. et al., 2020; Zheng et al., 2020; Pan et al., 2021; Qu et al., 2021); interestingly, miR-29a has been considered as a potential therapeutic target for HIV eradication, because of its binding to Nef viral protein, critical for viral persistence and release, and binding to the 3′UTR region of the HIV genome, mediating the transport of the virus to P-bodies (Ahluwalia et al., 2008; Nathans et al., 2009). This evidence concerns the gene S100B and breast cancer.